RUNX2 and primary cutaneous T-cell non-Hodgkin lymphoma: Taken together, these data confirm that RUNX2 is highly expressed by malignant CD4+ T-cells in a subset of MF patients at early CTCL stages, and higher RUNX2 expression was detected in Pautrier’s microabscesses in early-stage disease in patients who progressed to advanced stages.